Anticancer Drugs Durvalumab Oncology Pharmacology Physiotherapy

Durvalumab (Dosage Duration-1)

In this article we will discuss Durvalumab (Dosage Duration-1)

In this article, we will discuss Durvalumab (Dosage Duration-1). So, let’s get started.

Unresectable stage III NSCLC

  • Until disease progression, unacceptable toxicity, or a maximum of 12 months

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.